A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers -: I.: Manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations

被引:221
作者
Khan, MZI [1 ]
Prebeg, Z [1 ]
Kurjakovic, N [1 ]
机构
[1] PLIVA DD, Res Inst, Drug Dev Dept, Zagreb 10000, Croatia
关键词
colon targeted drug delivery; mesalazine; 5-amino salicylic acid; aqueous film coating; pH-dependent delivery system; extended release tablet;
D O I
10.1016/S0168-3659(98)00151-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Lactose-based placebo tablets were coated using various combinations of two methacrylic acid copolymers, Eudragit (R) L100-55 and Eudragit (R) S100, by spraying from aqueous systems. The Eudragit (R) L100-55-Eudragit (R) S100 combinations (w/w) studied were 1:0, 4:1, 3:2, 1:1, 2:3, 1:4, 1:5 and 0:1. The coated tablets were tested in vitro for their suitability for pH dependent colon targeted oral drug delivery. The same coating formulations were then applied on tablets containing mesalazine as a model drug and evaluated for in vitro dissolution rates under various conditions. The disintegration data obtained from the placebo tablets demonstrate that disintegration rate of the studied tablets is dependent on: (i) the polymers combination used to coat the tablets, (ii) pH of the disintegration media, and (iii) the coating level of the tablets. Dissolution studies performed on the mesalazine tablets further confirmed that the release profiles of the drug could be manipulated by changing the Eudragit (R) L100-55 and Eudragit (R) S100 ratios within the pH range of 5.5 to 7.0 in which the individual polymers are soluble respectively, and a coating formulation consisting of a combination of the two copolymers can overcome the issue of high gastrointestinal (GI) pH variability among individuals. The results also demonstrated that a combination of Eudragit (R) L100-55 and Eudragit (R) S100 can be successfully used from aqueous system to coat tablets for colon targeted delivery of drugs and the formulation can be adjusted to deliver drug at any other desirable site of the intestinal region of the GI tract on the basis of pH variability. For colon targeted delivery of drugs the proposed combination system is superior to tablets coated with either Eudragit (R) L100-55 or Eudragit (R) S100 alone. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 10 条
[1]   TARGETING DRUGS TO THE COLON - DELIVERY SYSTEMS FOR ORAL-ADMINISTRATION [J].
ASHFORD, M ;
FELL, JT .
JOURNAL OF DRUG TARGETING, 1994, 2 (03) :241-257
[2]   AN INVITRO INVESTIGATION INTO THE SUITABILITY OF PH-DEPENDENT POLYMERS FOR COLONIC TARGETING [J].
ASHFORD, M ;
FELL, JT ;
ATTWOOD, D ;
WOODHEAD, PJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 91 (2-3) :241-245
[3]   Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms [J].
Dressman, JB ;
Amidon, GL ;
Reppas, C ;
Shah, VP .
PHARMACEUTICAL RESEARCH, 1998, 15 (01) :11-22
[4]   MEASUREMENT OF GASTROINTESTINAL PH PROFILES IN NORMAL AMBULANT HUMAN-SUBJECTS [J].
EVANS, DF ;
PYE, G ;
BRAMLEY, R ;
CLARK, AG ;
DYSON, TJ ;
HARDCASTLE, JD .
GUT, 1988, 29 (08) :1035-1041
[5]  
Khan MZI, 1996, INT J PHARM, V140, P131
[6]  
Ramusen S.N., 1983, GASTROENTEROLOGY, V85, P1350
[7]   DISPOSITION OF 5-AMINOSALICYLIC ACID BY 5-AMINOSALICYLIC ACID-DELIVERING COMPOUNDS [J].
RIJK, MCM ;
VANSCHAIK, A ;
VANTONGEREN, JHM .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1988, 23 (01) :107-112
[8]   A NEW APPROACH TO THE ORAL-ADMINISTRATION OF INSULIN AND OTHER PEPTIDE DRUGS [J].
SAFFRAN, M ;
KUMAR, GS ;
SAVARIAR, C ;
BURNHAM, JC ;
WILLIAMS, F ;
NECKERS, DC .
SCIENCE, 1986, 233 (4768) :1081-1084
[9]   DISSOLUTION PROFILES OF MESALAZINE FORMULATIONS INVITRO [J].
STOLK, LML ;
RIETBROEK, R ;
WILTINK, EH ;
TUKKER, JJ .
PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1990, 12 (05) :200-204
[10]   Studies on drug release from pectin/ethylcellulose film-coated tablets: a potential colonic delivery system [J].
Wakerly, Z ;
Fell, JT ;
Attwood, D ;
Parkins, D .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 153 (02) :219-224